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Hypertrophic cardiomyopathy (HCM) is a complex, yet rela-
tively common genetic cardiac disease and has been the
subject of intensive investigation since its first description in
1958. HCM is defined by the presence of an increased left
ventricular wall thickness that is not solely explained by
abnormal loading conditions. Histologically, HCM is
characterised as left ventricular hypertrophy due to an abnor-
mally hypertrophied muscular structure of predominantly the
septum (‘myocardial fibre disarray’) [1]. Approximately 30 %
of patients with HCM develop left ventricular outflow tract
(LVOT) obstruction under resting conditions [2–4]. By con-
vention, LVOTobstruction is defined as an instantaneous peak
Doppler LVOT gradient of>30 mmHg at rest or during phys-
iological provocation. A gradient of>50 mmHg is usually
considered to be the threshold at which LVOT obstruction
becomes haemodynamically significant.
Pharmacological therapy using negative inotropic agents
(non-vasodilating beta-blocking agents, calcium antagonists
in particular verapamil, and disopyramide) is effective in the
majority of patients. However, 5–10 % of patients experience
drug-refractory symptoms most likely due to an increased
LVOT gradient. In those patients, surgical septal myectomy
(Morrow procedure) has been advocated to reduce outflow
obstruction and relieve symptoms. However, over the years
there have been many controversies over the efficacy of
myectomy as there were, and still are, serious doubts about
the haemodynamic impact of the septal obstruction. Is HCM
due to an abnormal ejection or due to an abnormal filling of
the left ventricle; in other words, is HCM primarily a systolic
or a diastolic problem? On one side, it was Maron and
Braunwald (Minneapolis, Boston) who emphasised the im-
portance of the obstruction [5], on the other hand, Criley
(UCLA, California) and Murgo (San Antonio, Texas)
defended the filling theory [6, 7]. Still in the year 2010Murgo
wrote the following words in JACC [6]: there is no evidence
that outflow is compromised as a result of an LVOT gradient.
Such an understanding does not imply that elimination of
LVOT gradients is not potentially beneficial. Rather, one
hopes that when one does recommend an intervention to
eliminate such gradients, one understands that that interven-
tion is not designed to improve ejection itself. Of course this
was contradicted by Maron and Braunwald, who supported
the obstruction theory and therefore advocated the surgical
approach. It is also of interest to take notice of the paper by
Maron et al. [8], published in 2011(!) in the European Heart
Journal (EHJ), where they encouraged the European cardiol-
ogy and cardiothoracic-surgery community to reconsider sur-
gical septal myectomy as a treatment option for severely
symptomatic obstructive HCM patients within Europe. This
was based on the fact that the less invasive alcohol septal
ablation, introduced by Ulrich Sigwart (Geneva, London) in
1994, became more and more common practice in Europe
resulting in the virtual obliteration of the surgical option for
HCM patients in Europe [9].
What do the new ESC guidelines, published in the EHJ
October 2014 issue [10], teach us about the value of invasive
therapy in severely affected HCM patients? What is the cur-
rent status of myectomy, septal alcohol ablation and dual
chamber pacing? First of all, there are no data to support the
use of invasive procedures to reduce LVOT gradients in
asymptomatic patients, regardless of their severity. In symp-
tomatic patients, however, with LVOT gradients of>50 %,
surgical myectomy substantially reduces the LVOT gradient
in over 90 % of patients whereby long-term symptomatic
benefit is achieved in 70–80 % of patients with a long-term
survival comparable with that of the general population. In
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those patients myectomy has a Class I recommendation sig-
nifying that the procedure is recommended/indicated. The
main surgical complications are AV-nodal block, ventricular
septal defect and aortic regurgitation, but these complications
are uncommon in experienced centres using intraoperative
transoesophageal echocardiography guidance. Surgical mor-
tality for myectomy with mitral intervention is 3–4 %.
Regarding the value of alcohol septal ablation, there are no
randomised trials comparing surgery and alcohol septal abla-
tion but several meta-analyses have shown that both proce-
dures improve functional status with similar procedural mor-
tality [11]. Alcohol septal ablation is the preferred option in
patients with mid-ventricular obstruction and appropriate cor-
onary anatomy [12]. However, the less invasive version of the
septal reduction therapy comes at a price: a larger number of
right and left bundle branch blocks, a higher risk on total AV
blocks (7–20 %) requiring permanent pacemaker implanta-
tions, and larger residual LVOT gradients [13]. The new
guidelines therefore state that septal myectomy, rather that
alcohol septal ablation, is recommended (Class I) in patients
with an indication for septal reduction therapy who also have
other lesions requiring surgical interventions (lesions of
valves and papillary muscles). It is also imperative that, be-
cause of the variability of the septal blood supply, myocardial
contrast echocardiography is essential prior to alcohol injec-
tion. If, for instance, the contrast agent cannot be localised
exclusively to the basal septum, the procedure should be
abandoned. Recently, septal myocardial ablation using micro-
sphere embolisation was proposed as an alternative to alcohol
to treat patients with HCM [14].
Regarding the value of dual-chamber pacing, only three
small randomised placebo-controlled studies have reported
reductions in LVOT obstruction gradients but variable im-
provements in symptoms and quality of life [15]. A recent
Cochrane review concluded that the data on the benefits of
pacing are based on physiological measures and they lack
information on clinically relevant endpoints. As a result, car-
diac pacing in HCMhas a Class IIb recommendation implying
that the usefulness/efficacy of the treatment/procedure is less
well established by evidence/opinion.
To summarise, the authors of the new HCM guideline have
stayed away from the controversy between LVOT obstruction
versus left ventricular emptying as the most important functional
parameter in HCM patients. Obviously, they have implicitly
chosen for the LVOT gradient as the key determinant in HCM.
Consequently, the new guidelines do support the use of septal
reduction therapy, i.e. myectomy and alcohol septal ablation, in
symptomatic patients with an LVOT gradient>50 mmHg pro-
vided that the septal reduction therapy is performed by experi-
enced operators working as a part of a multidisciplinary team
expert in the management of HCM. With these precautions in
mind -in particular for alcohol septal ablation- these invasive
procedures have a Class I recommendation, indicating that there
is nowadays sufficient evidence and/or general agreement that
these procedures are beneficial, useful, and effective. However,
experienced hands are a conditio sine qua non.
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